As the federal government scrutinizes various programs that provide some form of assistance to patients, drug makers are responding inconsistently to the legal hazards, according to a new survey.
Approximately one-third of the companies queried say they have altered procedures for funding independent charities that provide financial assistance to patients, but very few are regularly monitoring or auditing the activities of their patient services teams. And 25 percent of drug makers report that they provide patient services, such as copay cards, to people using their medicines for unapproved uses.
About the Author Reprints
An opioid 10 times faster than fentanil is quiet impressive.